Aktis Oncology (NASDAQ:AKTS) Stock Price Up 6.6% – Should You Buy?

Aktis Oncology (NASDAQ:AKTS)’s stock price shot up 6.6% on Tuesday . The stock traded as high as $22.12 and last traded at $22.0490. 46,609 shares traded hands during mid-day trading, a decline of 84% from the average session volume of 297,901 shares. The stock had previously closed at $20.69.

Analysts Set New Price Targets

Several research firms recently weighed in on AKTS. Raymond James Financial began coverage on shares of Aktis Oncology in a research note on Monday. They issued a “strong-buy” rating and a $40.00 target price for the company. HC Wainwright raised their target price on shares of Aktis Oncology from $33.00 to $35.00 and gave the company a “buy” rating in a research note on Tuesday, June 2nd. William Blair began coverage on shares of Aktis Oncology in a research note on Wednesday, April 29th. They issued an “outperform” rating for the company. Finally, Weiss Ratings cut shares of Aktis Oncology from a “sell (d+)” rating to a “sell (d)” rating in a research note on Tuesday, June 9th. One investment analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat.com, Aktis Oncology currently has an average rating of “Moderate Buy” and an average price target of $34.00.

Aktis Oncology Price Performance

The business’s 50 day simple moving average is $19.29.

Aktis Oncology (NASDAQ:AKTS) last released its quarterly earnings results on Monday, March 30th. The technology company reported ($18.17) earnings per share (EPS) for the quarter. The company had revenue of $1.87 million during the quarter. Equities analysts forecast that Aktis Oncology will post -1.62 EPS for the current year.

About Aktis Oncology

Aktis Oncology (NASDAQ: AKTS) is a biotechnology company focused on the discovery and development of new therapies for cancer. The firm concentrates on advancing oncology candidates through research and development with the goal of addressing unmet medical needs in oncology. Its work emphasizes targeted and precision approaches intended to improve the safety and efficacy profiles of cancer treatments.

The company’s activities include laboratory research, preclinical studies and clinical development as it advances its pipeline programs toward regulatory milestones.